The Affirm Prone Breast Biopsy System - Hologic extends a classic specialty tool

Affirm Prone Breast Biopsy System from Hologic targets precise breast lesion sampling with integrated 2D and optional 3D imaging in US hospitals. Anyone holding Hologic stock (NASDAQ: HOLX, ISIN US4364401012) should know this product.

By Daniel Foster, ad hoc news Classics & Longsellers Desk. Reviewed July 05, 2026, 3:19 AM ET. Details in the imprint.

Affirm Prone Breast Biopsy System from Hologic sits low in a dim procedure room, its padded table and metal gantry framed by soft monitor glow and the faint hum of imaging equipment. A radiology nurse adjusts the arm support, checking skin contact and cable slack before the next biopsy. This is not a new machine, but a long-running workhorse in US breast centers, designed to help radiologists sample suspicious lesions with steady positioning and accurate targeting under stereotactic guidance.

How the Affirm Prone system works

The Affirm Prone Breast Biopsy System is Hologic’s dedicated stereotactic prone table for breast biopsies, built to let patients lie face down while the breast is gently drawn into the imaging field and compressed for accurate needle placement. Radiologists can then target calcifications and masses using 2D digital stereotactic images, with the option to pair the system with Hologic’s tomosynthesis platforms for three-dimensional guidance in some configurations. The core promise is simple: stable positioning, clear visualization, and efficient tissue sampling in a controlled setting.

On Hologic’s product material, the Affirm Prone system is described as providing patient access and procedural efficiency for stereotactic breast biopsy, with features such as motorized vertical motion to optimize breast presentation and an ergonomic table design intended to keep patients comfortable during procedures that can run 30 minutes or longer. In practice, radiologists often combine the table with vacuum-assisted biopsy devices to obtain multiple cores through a single insertion, reducing needle passes and potentially cutting procedure time compared with older manual setups.

Patient comfort and workflow in US clinics

Walk into a mid-size US breast imaging center and you may see the Affirm Prone table parked in a dedicated biopsy room, with its rectangular top, cut-out opening, and under-table imaging unit. Patients lie prone, lowering the target breast into the opening, while technologists adjust compression and positioning using hand controls. In many facilities, the system is paired with wall-mounted monitors that show stereotactic coordinates and digital images in real time, so the radiologist can plan needle trajectory before making the skin puncture.

According to breast imaging specialists quoted in industry conference sessions, including radiologist Dr. Susan Harvey from Hologic’s medical team, prone stereotactic systems are still valued for patient stability and the ability to keep the biopsy field isolated from the rest of the body. For some patients, lying face down can feel more private and less visually stressful than sitting upright. Technologists also describe the Affirm Prone layout as helpful for workflow: instruments, biopsy cartridges, and specimen containers are all arranged around the opening, minimizing how far they have to reach or twist during a busy day of procedures.

Technical features and integration

From a technical standpoint, the Affirm Prone Breast Biopsy System is a motorized table integrated with an X-ray imaging unit that can acquire stereotactic pairs of images, typically at two angles, to compute three-dimensional coordinates for the lesion. Once the target position is confirmed, the radiologist sets biopsy coordinates on the control console, and the system guides needle trajectory. The hardware is designed to accept compatible biopsy devices, including Hologic’s own vacuum-assisted systems, which snap into a cradle under the table.

The system’s design focuses on stability: compression paddles hold the breast steady, and the table structure supports the patient’s body weight while minimizing motion transfer to the target area. Imaging technologists often point out that the prone position can reduce respiratory motion artifact compared with some upright setups, because the chest is down and the arm position is controlled. There are also safety features such as emergency stop buttons and mechanical interlocks that prevent imaging motion while the clinician’s hands are in the field.

Affirm Prone versus upright biopsy systems

Hologic also sells upright biopsy solutions like the Affirm Upright Breast Biopsy System, which mount on tomosynthesis mammography units and allow biopsies with the patient seated rather than facedown. In recent years, many US breast imaging centers have invested heavily in upright tomosynthesis-guided biopsy because it can streamline diagnostics: the same mammography room can be used for screening, diagnostic workup, and biopsy, which reduces room count and capital expense per procedure. That has shifted some new installations toward upright platforms.

Still, the Affirm Prone Breast Biopsy System occupies a specific niche, particularly in sites that have older mammography units or prefer to keep biopsies in a separate, more controlled space. Some radiologists like the tactile familiarity of a dedicated prone table, arguing that it keeps the biopsy workflow distinct from routine mammography and helps staff mentally separate screening from invasive procedures. Others highlight that prone positioning can be helpful for certain lesion locations or for patients who feel anxious sitting upright during needle insertion.

Clinical use cases and specimen handling

In everyday practice, the Affirm Prone system is used mainly for stereotactic biopsies of non-palpable lesions seen on mammography, particularly microcalcifications that may indicate ductal carcinoma in situ or early invasive breast cancer. Because these calcifications are often not visible on ultrasound, stereotactic guidance with prone tables remains an important diagnostic route. The radiologist identifies the lesion on scout images, sets the stereotactic geometry, and then performs the biopsy while technologists prepare specimen containers and labeling.

Once tissue cores are obtained, they are typically sent in formalin jars to pathology, where histologic analysis determines whether the lesion is benign, atypical, or malignant. Hologic’s system does not change the pathology workflow, but by enabling accurate sampling, it contributes directly to the quality of diagnostic information. Pathologists sometimes receive small calcification-rich cores from stereotactic procedures, which require careful microtomy and staining to interpret. For patients, the key outcome is clear: either reassurance with benign results or a precise diagnosis that enables timely treatment planning.

Training, maintenance, and reliability

Because the Affirm Prone Breast Biopsy System is a capital piece of imaging equipment, hospitals invest in training for radiologists, technologists, and biomedical engineers who maintain the system over its lifespan. Hologic offers installation and training programs, and hospital teams often create local protocols covering positioning, sterile technique around the breast opening, and emergency stop procedures if a patient feels unwell during the biopsy. Some centers also run simulation training with volunteers or phantoms to help new staff gain comfort with the console and positioning controls.

Maintenance includes regular checks of mechanical components, compression paddles, imaging detectors, and calibration markers. Biomedical engineers typically follow OEM guidelines on X-ray tube performance and image quality tests, and they document preventive service visits to meet regulatory and accreditation requirements. Radiologists depend on the system’s reliability: a prone table failure during the day can disrupt the biopsy schedule and force rescheduling of patients, which is logistically difficult and emotionally stressful for those waiting on results.

US availability and reimbursement environment

In the US, the Affirm Prone Breast Biopsy System is offered primarily to hospitals and imaging centers that perform a moderate to high volume of mammography-guided biopsies. The system is sold through Hologic’s capital equipment sales channels, and while the company does not publish list pricing openly, industry procurement data suggests that stereotactic prone tables sit in the six-figure range when bundled with imaging units and installation services. Purchasing decisions are typically tied to overall breast imaging strategy, including tomosynthesis adoption and biopsy volume forecasts.

Reimbursement for stereotactic breast biopsy in the US flows through established CPT codes and Medicare outpatient payment systems, with specific facility and professional components. That means the Affirm Prone system’s financial performance at a given site depends on biopsy volume and payer mix. For larger health systems, the table can be part of a breast health center strategy that includes screening, diagnostic, and surgical services. Investors watching shares of Hologic often look at this breast health segment’s capital sales as a bellwether for imaging demand, even if individual product revenue is not broken out publicly.

Hologic, breast health segment, and stock context

Hologic positions the Affirm Prone Breast Biopsy System within its broader Breast & Skeletal Health division, which also includes Selenia Dimensions and other tomosynthesis mammography platforms, as well as related biopsy tools. CEO Stephen P. MacMillan has consistently framed breast health as a strategic focus area, highlighting in past earnings calls that investments in imaging and interventional devices aim to improve women’s health outcomes while supporting predictable recurring revenue. The Affirm Prone system is a mature product in this lineup, but it still contributes through capital upgrades, replacement cycles, and service contracts at installed sites.

Hologic stock (NASDAQ: HOLX, ISIN US4364401012) trades in the US as a medical technology name with significant exposure to diagnostic imaging and women’s health, and investors tend to analyze the company by segment rather than by individual product. The steady, if unspectacular, role of systems like Affirm Prone in breast biopsy suites is part of the long-tail revenue profile that underpins this segment’s stability, alongside newer technologies in tomosynthesis screening and molecular diagnostics.

Key facts on Affirm Prone Breast Biopsy System

• Product: Affirm Prone Breast Biopsy System
• Manufacturer: Hologic Inc.
• Category: Classics & longsellers breast biopsy table
• Launch: Commercially available for several years as a stereotactic prone biopsy solution; Hologic promotes it as an established tool in its breast health portfolio.
• MSRP / Price: Not publicly disclosed; industry estimates place bundled stereotactic prone systems in the approximate six-figure USD range for US hospitals.
• Availability: Sold to US and international hospitals and breast imaging centers through Hologic’s capital equipment channels.
• Target audience: Radiologists, breast imaging centers, and hospital administrators seeking a dedicated prone stereotactic biopsy solution for mammography-detected lesions.
• Standout / USP: Dedicated prone table design that isolates the biopsy field, supports patient comfort face down, and integrates with stereotactic imaging for precise targeting of microcalcifications and non-palpable breast lesions.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.